Dose-dense temozolomide: is it still promising?

Neurologia Medico-chirurgica
Motoo Nagane

Abstract

Glioblastoma (GBM) has proven to be incurable despite recent progress on its standard of care using temozolomide (TMZ) as the main trunk of initial therapy for newly diagnosed GBM. One of the main reasons accounting for the dismal prognosis is attributed to lack of active therapeutic regimens at recurrence. Since TMZ is the most active cytotoxic agent against GBM, and the standard dosing of TMZ has shown favorable safety profile in clinical trials, re-challenge with TMZ in increased dose density schedules for recurrent tumors that have evaded from prior standard TMZ therapy appears to be a rational approach and has been intensively exploited. A number of phase II clinical trials using different alternating scheduling of dose-dense TMZ (ddTMZ) have shown superior efficacy over the standard TMZ or historical controls with other alkylating agents including nitrosoureas and procarbazine. One ddTMZ schedule, consisting of a 21-days on/7-days off regimen was applied to newly-diagnosed GBM as the adjuvant monotherapy after completion of combined radiation and TMZ and failed to demonstrate survival benefit in a large phase III trial (RTOG 0525). Thus its role in TMZ-pretreated, recurrent GBM should be carefully pursuit in randomized tr...Continue Reading

References

Jan 1, 1995·Progress in Nucleic Acid Research and Molecular Biology·A E PeggR C Moschel
Mar 27, 1999·Neurologia Medico-chirurgica
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E T WongW K Yung
Nov 9, 2000·The New England Journal of Medicine·M EstellerJ G Herman
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stanton L Gerson
Apr 2, 2004·Nature Reviews. Cancer·Stanton L Gerson
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Mar 11, 2005·The New England Journal of Medicine·Monika E HegiRoger Stupp
Jun 14, 2005·Neurological Research·Hongguang HuangRolf Mentlein
Feb 16, 2006·Neurology·A TosoniA A Brandes
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antje WickWolfgang Wick
Mar 22, 2008·Neuro-oncology·Kathleen R LambornUNKNOWN North American Brain Tumor Consortium
Sep 2, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Monika E HegiMark R Gilbert
Sep 6, 2008·Neuro-oncology·Wolfgang WickMichael Weller
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Teri N KreislHoward A Fine
Jan 2, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Santosh KesariPatrick Y Wen
Feb 26, 2009·Journal of Neurology·Antje WickPeter Hau
Jun 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer L ClarkeLauren E Abrey
Jul 14, 2009·Journal of Neuro-oncology·Marc C Chamberlain, Sandra K Johnston
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry S FriedmanTimothy Cloughesy
Dec 10, 2009·Nature Reviews. Neurology·Michael WellerMonika E Hegi
Jan 13, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J J C VerhoeffD J Richel
Feb 4, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang WickHoward A Fine
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James R PerryJean-François Pouliot
Sep 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael BradaSiow-Ming Lee
Sep 30, 2010·Journal of Neuro-oncology·Ufuk AbaciogluMeric Sengoz
Jun 4, 2011·Neuro-oncology·Wolfgang WickMichael Platten
Jul 28, 2011·Cancer·Annick DesjardinsJames J Vredenburgh
Mar 8, 2012·Journal of Neuro-oncology·Walter TaalMartin J van den Bent
May 1, 2012·Journal of Neuro-oncology·Dagmar BeierChristoph P Beier
May 15, 2012·The Lancet Oncology·Wolfgang WickUNKNOWN NOA-08 Study Group of Neuro-oncology Working Group (NOA) of German Cancer Society
Jul 31, 2012·Japanese Journal of Clinical Oncology·Motoo NaganeMasao Matsutani
Apr 5, 2013·Neuro-oncology·Andrew D NordenPatrick Y Wen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.